5FU to S-1

erification of effectiveness by changing from 5FU to S-1 in chemoradiotherapy

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1080223854

Enrollment

Registered

2018-03-27

Start date

2018-03-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anal cancer, esophageal cancer, head and neck cancer

Interventions

investigational material(s) Generic name etc : TS1 INN of investigational material : tegaful gimeracil oteracil Therapeutic category code : 422 Antimetabolic agents Dosage and Administration for Inves

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Cases for which chemoradiotherapy including continuous administration of 5FU is indicated Cases in which written consent has been obtained from the patient

Exclusion criteria

Exclusion criteria: Cases where oral ingestion or tube administration is difficult Cases using phenytoin, warfarin potassium, and flucytosine Cases with uncontrolled diabetes Cases with severe mental illness who may have difficulty participating in the study Cases with serious drug allergies Other cases that the doctor in charge judged to be inappropriate for registration of this study

Design outcomes

Primary

Measure	Time frame
safety Treatment completion rate	—

Secondary

Measure	Time frame
safety Acute adverse event rate, complete response rate, progression-free survival, overall survival, 3-year survival rate	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026